Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.
$BFLY
Medical Electronics
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 2)
|
Butterfly Network, Inc. (Name of Issuer) |
Class A common stock, par value $0.0001 per share (Title of Class of Securities) |
124155102 (CUSIP Number) |
12/31/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 124155102 |
| 1 | Names of Reporting Persons
Fosun Industrial Co., Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
HONG KONG
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
10,716,630.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: Rows 6, 8 and 9: Consists of 10,716,630 shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock") of Butterfly Network, Inc. (f/k/a Longview Acquisition Corp.) (the "Issuer") held by Fosun Industrial Co., Limited.
Row 11: Calculated based on 226,175,175 shares of Class A Common Stock of the Issuer outstanding as of October 21, 2025 as reported in the Issuer's Form 10-Q filed with the Securities Exchange Commission on October 31, 2025.
SCHEDULE 13G
|
| CUSIP No. | 124155102 |
| 1 | Names of Reporting Persons
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
CHINA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
10,716,630.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
4.7 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
Comment for Type of Reporting Person: Rows 6, 8 and 9: Consists of 10,716,630 shares of Class A Common Stock of the Issuer held by Fosun Industrial Co., Limited.
Row 11: Calculated based on 226,175,175 shares of Class A Common Stock of the Issuer outstanding as of October 21, 2025 as reported in the Issuer's Form 10-Q filed with the Securities Exchange Commission on October 31, 2025.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Butterfly Network, Inc. | |
| (b) | Address of issuer's principal executive offices:
1600 District Avenue Burlington, MA, 01803 | |
| Item 2. | ||
| (a) | Name of person filing:
This Statement is being filed on behalf of (i) Fosun Industrial Co., Limited ("Fosun Industrial") and (ii) Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"). Fosun Industrial and Fosun Pharma are each referred to herein as a "Reporting Person" and are collectively referred to herein as the "Reporting Persons".
Fosun Industrial is principally engaged in foreign investment, sale and consultancy service of Chinese and western medicine, diagnostic reagent, medical device products and relevant import and export business.
Fosun Pharma is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services, and further extends its capabilities in pharmaceutical commerce through its associated company. | |
| (b) | Address or principal business office or, if none, residence:
The address of the principal business office for Fosun Industrial is Room 1917, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong. The address of the principal business office for Fosun Pharma is No. 1289 Yishan Road (Building A, Fosun Technology Park), Shanghai 200233, People's Republic of China ("PRC"). | |
| (c) | Citizenship:
Fosun Industrial is a company incorporated under the laws of Hong Kong with limited liability. Fosun Industrial is a wholly-owned subsidiary of Fosun Pharma.
Fosun Pharma is a joint stock company incorporated in the PRC with limited liability, the H shares and A shares of which are listed and traded on the Main Board of The Stock Exchange of Hong Kong Limited (the "SEHK") and the Shanghai Stock Exchange, respectively. As of December 31, 2025, Fosun Pharma was a subsidiary of, and was beneficially held as to approximately 36.00% by, Shanghai Fosun High Technology (Group) Co. Ltd. ("Fosun High Technology") and 0.22% by Fosun International Limited ("Fosun International").
As of December 31, 2025, Fosun High Technology was a wholly-owned subsidiary of Fosun International and performed its parent company's business operation in the PRC. Fosun International is a global innovation-driven consumer group which is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in health, happiness and wealth. Fosun International is a company incorporated in Hong Kong with limited liability, whose shares are listed and traded on the Main Board of the SEHK. As of December 31, 2025, Fosun International was a subsidiary of, and was beneficially held as to approximately 72.50% by, Fosun Holdings Limited ("Fosun Holdings"). Fosun Holdings is an investment holding company. As of December 31, 2025, Fosun Holdings was a wholly-owned subsidiary of Fosun International Holdings Ltd. ("Fosun International Holdings"). Fosun International Holdings is an investment holding company. As of December 31, 2025, Fosun International Holdings was beneficially held as to approximately 85.29% by Guo Guangchang and 14.71% by Wang Qunbin. Guo Guangchang controls Fosun International Holdings and could therefore be deemed the beneficial owner of the securities held by Fosun Industrial. | |
| (d) | Title of class of securities:
Class A common stock, par value $0.0001 per share | |
| (e) | CUSIP No.:
124155102 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
See Item 9 of the cover pages to this Statement for the aggregate number of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025. | |
| (b) | Percent of class:
See Item 11 of the cover pages to this Statement for the percentage of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025 | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
See Item 5 of the cover pages to this Statement for the number of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025 as to which there is sole power to vote or direct the vote. | ||
| (ii) Shared power to vote or to direct the vote:
See Item 6 of the cover pages to this Statement for the number of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025 as to which there is shared power to vote or direct the vote. | ||
| (iii) Sole power to dispose or to direct the disposition of:
See Item 7 of the cover pages to this Statement for the number of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025 as to which there is sole power to dispose or direct the disposition. | ||
| (iv) Shared power to dispose or to direct the disposition of:
See Item 8 of the cover pages to this Statement for the number of shares of Class A Common Stock that are beneficially owned by each Reporting Person as of December 31, 2025 as to which there is shared power to dispose or direct the disposition. | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
|
Ownership of 5 percent or less of a class
| ||
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
Exhibit Information
|
99.1 Joint Filing Agreement dated February 22, 2021 by and between Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (incorporated by reference to Exhibit 99.1 to that certain Schedule 13G filed on February 22, 2021 by the Reporting Persons with the Securities and Exchange Commission). |